Abstract  Description  Claims  Drawing  Search report  Cited references 

US5942251A   [0056] 
EP0865789A3   [0056] 
BE1006872A   [0056] 
US20030040537A   [0063] 
US6077539A   [0063] 
WO005781A3   [0063] 
EP1165044A2   [0063] 
CN1347313T   [0063] 
AU0038825A5   [0063] 
US5756483A   [0063] 
EP0689438A1   [0063] 
AU6428894A1   [0063] 
WO9422445A3   [0063] 
US20030017994A   [0063] 
US6488648B   [0064] 
US6451287B   [0064] 
US6395300B   [0064] 
US6395299B   [0064] 
US6390291B   [0064] 
US6315122B   [0064] 
US6179118B   [0064] 
US6119853A   [0064] 
US6406681B   [0064] 
US5720940A   [0064] 
US5683677A   [0064] 
US5776434A   [0064] 
US5776573A   [0064] 
US6153173A   [0064] 
US6309624B   [0064] 
US6013245A   [0064] 
US6200549B   [0064] 
US6221339B   [0064] 
US6236747B   [0064] 
US6251368B   [0064] 
US6306369B   [0064] 
US6253762B   [0064] 
US6149892A   [0064] 
US6284287B   [0064] 
US5744123A   [0064] 
US5916540A   [0064] 
US5955439A   [0064] 
US5992306A   [0064] 
US5849265A   [0064] 
US5833950A   [0064] 
US5817293A   [0064] 
US6143277A   [0064] 
US6131566A   [0064] 
US5736124A   [0064] 
US5696744A   [0064] 
US6200293B   [0065] 
US6120613A   [0065] 
US6183782B   [0065] 
US6129905A   [0065] 
US6309623B   [0065] 
US5619984A   [0065] 
US4524769A   [0065] 
US5740793A   [0065] 
US5875766A   [0065] 
US6098619A   [0065] 
US6012454A   [0065] 
US5972388A   [0065] 
US5922306A   [0065] 
US5813597A   [0065] 
US572012A   [0081]  [0082] 
WO2005025506A2   [0081]  [0082]  [0082]  [0115] 

Headache   [0002] 
Neurology   [0003] 
Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine   [0004] 
Neurology   [0008]  [0062] 
Headache   [0008] 
Headache   [0008] 
Headache   [0008]  [0008] 
Neurology   [0008] 
Headache   [0008] 
Arch. Neurol.   [0008]  [0009] 
Headache   [0008] 
Arch. Neurol.   [0009] 
A double blind study of subcutaneous dihydroergotamine versus subcutaneous sumatriptan in the treatment of acute migraine   [0010] 
Neurol Clin.   [0056] 
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy   [0060]  [0093] 
Repetitive intravenous dihydroergotamine as therapy for intractable migraine   [0062] 
The Science and Practice of Pharmacy   [0066] 
Guidelines for controlled clinical trials of drugs in migraine   [0086] 
Dihydroergotamine and its metabolite, 8-hydroxy-dihydroergotamine, as 5-HT1A receptor agonists in the rat brain   [0093] 
Trends Pharmacol. Sci.   [0095] 
PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor   [0096] 
Eur. J. Neurosci.   [0096] 
British Journal of Pharmacology   [0096] 
Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175   [0097] 
Aellig, W.H. Pharmacokinetic investigation of oral and IV dihydroergotamine in healthy subjects   [0109]